Clinical effect of arsenic trioxide combined with all-trans retinoic acid for acute promyelocytic leukemia and the impact on quality of life
SU Yila;LYU Aie;PIAN Xiaoqin;GAO Da;Department of Hematology,Affiliated Hospital of Inner Mongolia Medical University;Department of Medicine,New District Hospital of Hohhot;
Objective To observe the curative effect of arsenic trioxide(ATO) combined with all-trans retinoic acid(ATRA) for newly diagnosed acute promyelocytic leukemia(APL), and its impact on quality of life. Method 92 patients with APL were included in the analysis, and were stratified as control group or study group by respective treatment regimens, with 46 cases in each, the control group received ATRA, while the study group was given ATO and ATRA. The time to complete response(CR) during induction period, the negative rate of promyelocytic leukemia retinoic acid receptor α(PML-RARα), the volume of fresh frozen plasma and PLT transfusion, and adverse reactions were compared between the two groups. The quality of life was evaluated by EORTC QLQ-C30. Result For study group, during the induction period, the time to CR was(27.6±5.3) d, the volume of fresh frozen plasma and PLT transfusion was(830.2±75.3) ml and(33.1±8.8) U, the negative rate of PML-RARα was 100%, all were better than those in control group at(33.8±6.6) d,(942.8±67.6) ml,(52.3±12.8) U and 82.6%(P0.05). The score of general health evaluated using EORTC QLQ-C30 was higher in study group than that in control group(P0.05). The incidence of adverse reactions was similar in both groups(P0.05). Conclusion ATO combined with ATRA is effective and safe for newly diagnosed APL, and could improve quality of life, so is worthy of widely clinical use.
【CateGory Index】： R733.71